Grozinsky-Glasberg, Simona; Barak, Dganit; Fraenkel, Merav; Walter, Martin A; Müeller-Brand, Jan; Eckstein, Joseph; Applebaum, Liat; Shimon, Ilan; Gross, David J (2011). Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer, 117(7), pp. 1377-85. New York, N.Y.: John Wiley & Sons 10.1002/cncr.25646
Full text not available from this repository. (Request a copy)Gastrinomas, a rare group of neuroendocrine tumors, are responsible for severe peptic disease and diarrhea. Although symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs), data are limited regarding the possible antitumor effect of the peptide receptor radioligand therapy (PRRT) with radiolabeled SSAs in gastrinoma patients. The goal of this study was to assess the effect of PRRT on symptoms, gastrin secretion, and tumor load in patients with progressive malignant gastrinomas.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine |
UniBE Contributor: |
Walter, Martin Alexander |
ISSN: |
0008-543X |
Publisher: |
John Wiley & Sons |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:09 |
Last Modified: |
05 Dec 2022 14:00 |
Publisher DOI: |
10.1002/cncr.25646 |
PubMed ID: |
21425137 |
Web of Science ID: |
000288561700007 |
URI: |
https://boris.unibe.ch/id/eprint/1028 (FactScience: 201701) |
Actions (login required)
 |
Edit item |